Heavily Shorted Novavax Soars As FDA Panel Decides On Next Covid Shot

Heavily Shorted Novavax Soars As FDA Panel Decides On Next Covid Shot:

Shares of heavily shorted Novavax soared as much as 25% on Wednesday. Shares are up more than 400% since the end of April. Data from S3 Partners shows short interest topped 33% of the equity float.

* * *

PayPal: Donate in USD
PayPal: Donate in EUR
PayPal: Donate in GBP

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.